Anavex Life Sciences Corp. (NASDAQ:AVXL) saw an uptick in trading volume on Monday . 1,705,831 shares were traded during trading, an increase of 83% from the previous session’s volume of 932,861 shares.The stock last traded at $7.81 and had previously closed at $7.58.

Several research firms have commented on AVXL. Zacks Investment Research raised Anavex Life Sciences Corp. from a “hold” rating to a “buy” rating and set a $5.00 price objective for the company in a research note on Tuesday, May 31st. Maxim Group reaffirmed a “buy” rating and set a $15.00 price objective on shares of Anavex Life Sciences Corp. in a research note on Wednesday, May 11th. Finally, FBR & Co reaffirmed a “buy” rating on shares of Anavex Life Sciences Corp. in a research note on Wednesday, June 22nd.

The firm’s market capitalization is $276.04 million. The stock has a 50-day moving average price of $4.79 and a 200 day moving average price of $4.75.

Anavex Life Sciences Corp. (NASDAQ:AVXL) last announced its earnings results on Wednesday, May 11th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.16) by $0.10. On average, analysts anticipate that Anavex Life Sciences Corp. will post ($0.34) earnings per share for the current year.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.